Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Personalized cancer therapy focuses on characterizing the relevant phenotypes of the patient, as well as the patient’s tumor, to predict the most effective cancer therapy. Historically, these methods have not proven predictive in regards to predicting therapeutic response. Emerging culture platforms are designed to better recapitulate the in vivo environment, thus, there is renewed interest in integrating patient samples into in vitro cancer models to assess therapeutic response. Successful examples of translating in vitro response to clinical relevance are limited due to issues with patient sample acquisition, variability and culture. We will review traditional and emerging in vitro models for personalized medicine, focusing on the technologies, microenvironmental components, and readouts utilized. We will then offer our perspective on how to apply a framework derived from toxicology and ecology towards designing improved personalized in vitro models of cancer. The framework serves as a tool for identifying optimal readouts and culture conditions, thus maximizing the information gained from each patient sample.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., van Es, J. H., van den Brink, S., van Houdt, W. J., Pronk, A., van Gorp, J., Siersema, P. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.050 · Cited by 3,753
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
The present and future role of microfluidics in biomedical research
Sackmann, E. K., Fulton, A. L., & Beebe, D. J. (2014) · Nature · doi:10.1038/nature13118 · Cited by 2,995
Self-citationThe third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817
Ankley, G. T., Bennett, R. S., Erickson, R. J., Hoff, D. J., Hornung, M. W., Johnson, R. D., Mount, D. R., Nichols, J. W., Russom, C. L., Schmieder, P. K., et al. (2009) · Environmental Toxicology and Chemistry · doi:10.1002/etc.34 · Cited by 2,734
Hydrogels as extracellular matrix mimics for 3D cell culture
Tibbitt, M. W., & Anseth, K. S. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22361 · Cited by 2,727
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 1×
“Even therapeutics that target the same cancer subtype can work through different mechanisms and have different risk factors for resistance (Gottesman, 2002; Normanno et al., 2005).”
BackgroundDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408 · cited 2×
“…organoids are advantageous because they can be cultured long term, are amenable to drug screening and retain histological, immunohistochemical and genetic features of the tissue they were derived from (Sato et al., 2011; Gao et al., 2014; Huang et al., 2015; van de Wetering et al., 2015).”
BackgroundThe causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Collagen reorganization at the tumor-stromal interface facilitates local invasion
Provenzano, P. P., Eliceiri, K. W., Campbell, J. M., Inman, D. R., White, J. G., & Keely, P. J. (2006) · BMC Medicine · doi:10.1186/1741-7015-4-38 · Cited by 1,804
Modeling Tissue Morphogenesis and Cancer in 3D
Yamada, K. M., & Cukierman, E. (2007) · Cell · doi:10.1016/j.cell.2007.08.006 · Cited by 1,751
Multicellular tumor spheroids: An underestimated tool is catching up again
Hirschhaeuser, F., Menne, H., Dittfeld, C., West, J., Mueller-Klieser, W., & Kunz-Schughart, L. A. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.01.012 · Cited by 1,674
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483 · cited 2×
“In hope of developing more robust cancer models, some groups have begun to incorporate additional microenvironment components factors into in vitro cancer models (Weaver et al., 1997; Kim, Stein, & O'Hare, 2004; Nyga, Cheema, & Loizidou, 2011; Shamir & Ewald, 2014).”
BackgroundMolecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299 · cited 2×
“…key features of the in vivo environment such as tissue structure, matrix composition, and immune component or stromal cells despite evidence suggesting the pivotal role each plays in cancer progression (Wang, Albo, & Tuszynski, 2002; Allinen et al., 2004; Place, Jin Huh, & Polyak, 2011).”
BackgroundCancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion
Dirat, B., Bochet, L., Dabek, M., Daviaud, D., Dauvillier, S., Majed, B., Wang, Y. Y., Meulle, A., Salles, B., Le Gonidec, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3323 · Cited by 1,134
Stromal gene expression defines poor-prognosis subtypes in colorectal cancer
Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., Sevillano, M., Palomo-Ponce, S., Tauriello, D. V. F., Byrom, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3225 · Cited by 1,070 · cited 2×
“It has been demonstrated that tumor-associated stroma undergoes extensive changes in gene expression and that a stromal transcript signature correlates with histological tumor grade (Tuxhorn et al., 2002; Chang et al., 2003; Calon et al., 2015).”
BackgroundSources of estrogen and their importance
Simpson, E. R. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00360-1 · Cited by 936 · cited 1×
“…receptor (ER) agonists include estrogen synthesis in the ovaries and local synthesis through conversion of he key events between a molecular initiating event and an adverse outcome. androgens to estrogens via aromatase (Williams & Phillips, 2000; Simpson, 2003; Mobley & Brueggemeier, 2004).”
BackgroundThree-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function
Zervantonakis, I. K., Hughes-Alford, S. K., Charest, J. L., Condeelis, J. S., Gertler, F. B., & Kamm, R. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210182109 · Cited by 872 · cited 2×
“…to evaluate changes that were previously difficult to quantify in vitro, including key events in cancer progression, such as invasion, angiogenesis, intravasation, and extravasation (Zervantonakis et al., 2012; Bischel, Beebe, & Sung, 2015; Jeon et al., 2015; Jimenez-Torres et al., 2015).”
BackgroundHuman 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation
Jeon, J. S., Bersini, S., Gilardi, M., Dubini, G., Charest, J. L., Moretti, M., & Kamm, R. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417115112 · Cited by 723 · cited 1×
“…to evaluate changes that were previously difficult to quantify in vitro, including key events in cancer progression, such as invasion, angiogenesis, intravasation, and extravasation (Zervantonakis et al., 2012; Bischel, Beebe, & Sung, 2015; Jeon et al., 2015; Jimenez-Torres et al., 2015).”
BackgroundThree-dimensional organotypic culture: experimental models of mammalian biology and disease
Shamir, E. R., & Ewald, A. J. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3873 · Cited by 719 · cited 2×
“In hope of developing more robust cancer models, some groups have begun to incorporate additional microenvironment components factors into in vitro cancer models (Weaver et al., 1997; Kim, Stein, & O'Hare, 2004; Nyga, Cheema, & Loizidou, 2011; Shamir & Ewald, 2014).”
BackgroundStromal cells in tumor microenvironment and breast cancer
Mao, Y., Keller, E. T., Garfield, D. H., Shen, K., & Wang, J. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9415-3 · Cited by 671 · cited 1×
“Cancer associated adipocytes (CAAs) become delipidated, obtain a fibroblast-like morphology and encourage cancer cell proliferation and invasion (Tan et al., 2011; Mao et al., 2013).”
Fundamentals of microfluidic cell culture in controlled microenvironments
Young, E. W. K., & Beebe, D. J. (2010) · Chemical Society Reviews · doi:10.1039/b909900j · Cited by 615 · cited 1×
“The fundamentals and applications of microfluidic in vitro models have been extensively reviewed (Morales et al., 1995; Khademhosseini, Langer, Borenstein, & Vacanti, 2006; Young & Beebe, 2010; Sackmann, Fulton, & Beebe, 2014).”
Self-citationLoessner, D., Stok, K. S., Lutolf, M. P., Hutmacher, D. W., Clements, J. A., & Rizzi, S. C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.07.064 · Cited by 602 · cited 5×
“…in a decreased drug resistance, suggesting that incorporation of at least some of these factors is necessary to accurately predict drug response (Loessner et al., 2010; Chitcholtan, Asselin, Parent, Sykes, & Evans, 2013; Gajewski, Schreiber, & Fu, 2013; Xu et al., 2013; Majety, Pradel, Gies, &…”
BackgroundInfluentialGene expression perturbation in vitro—A growing case for three-dimensional (3D) culture systems
Birgersdotter, A., Sandberg, R., & Ernberg, I. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.06.009 · Cited by 591
Multicellular spheroids in ovarian cancer metastases: Biology and pathology
Shield, K., Ackland, M. L., Ahmed, N., & Rice, G. E. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.11.032 · Cited by 412
Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells
Doisneau-Sixou, S. F., Sergio, C. M., Carroll, J. S., Hui, R., Musgrove, E. A., & Sutherland, R. L. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100179 · Cited by 333
Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids
Hsiao, A. Y., Torisawa, Y.-S., Tung, Y.-C., Sud, S., Taichman, R. S., Pienta, K. J., & Takayama, S. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.02.047 · Cited by 323 · cited 1×
“With growing recognition of the importance of 3D microenvironment, spheroids also can be generated in various biomaterials to achieve spheroid–ECM interactions (Hsiao et al., 2009; Loessner et al., 2010; Ong et al., 2010).”
BackgroundKondo, J., Endo, H., Okuyama, H., Ishikawa, O., Iishi, H., Tsujii, M., Ohue, M., & Inoue, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015938108 · Cited by 322 · cited 1×
“However, this studywas observational and the results were not applied clinically, so no correleation with patient response could be drawn (Kondo et al., 2011).”
Xu, Z., Gao, Y., Hao, Y., Li, E., Wang, Y., Zhang, J., Wang, W., Gao, Z., & Wang, Q. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.045 · Cited by 295
Calippe, B., Douin-Echinard, V., Delpy, L., Laffargue, M., Lélu, K., Krust, A., Pipy, B., Bayard, F., Arnal, J.-F., Guéry, J.-C., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902383 · Cited by 245 · cited 2×
“between ER activation and macrophage function (Calippe et al., 2010; Campbell et al., 2014).”
BackgroundChitcholtan, K., Asselin, E., Parent, S., Sykes, P. H., & Evans, J. J. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.09.012 · Cited by 173
Microfluidic model of ductal carcinoma in situ with 3D, organotypic structure
Bischel, L. L., Beebe, D. J., & Sung, K. E. (2015) · BMC Cancer · doi:10.1186/s12885-015-1007-5 · Cited by 110
Self-citationRegulation of aromatase expression in breast cancer tissue
Bulun, S. E., Lin, Z., Zhao, H., Lu, M., Amin, S., Reierstad, S., & Chen, D. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.03705.x · Cited by 83 · cited 1×
“They also produce unusually high levels of aromatase that greatly contribute to estrogen rich environment found in ER+breast cancer tissue (van Landeghem, Poortman,Nabuurs, & Thijssen, 1985; Santen et al., 1997; Mor et al., 1998; Bulun et al., 2009; Tan et al., 2011).”
BackgroundSastre-Serra, J., Nadal-Serrano, M., Pons, D. G., Roca, P., & Oliver, J. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.07.012 · Cited by 40
Kenny, P. A., Lee, G. Y., Myers, C. A., Neve, R. M., Semeiks, J. R., Spellman, P. T., Lorenz, K., Lee, E. H., Barcellos-Hoff, M. H., Petersen, O. W., et al. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.02.004 · Cited by 2
Cited by
Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80
Toward improved in vitro models of human cancer
Ayuso, J. M., Park, K.-Y., Virumbrales-Muñoz, M., & Beebe, D. J. (2021) · APL Bioengineering · doi:10.1063/5.0026857 · Cited by 40
Self-citationMicrophysiological model of renal cell carcinoma to inform anti-angiogenic therapy
Virumbrales-Muñoz, M., Ayuso, J. M., Loken, J. R., Denecke, K. M., Rehman, S., Skala, M. C., Abel, E. J., & Beebe, D. J. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121454 · Cited by 20
Self-citation
Metadata
- Authors
- Morgan, M. M., Johnson, B. P., Livingston, M. K., Schuler, L. A., Alarid, E. T., Sung, K. E., & Beebe, D. J.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 165
- Pages
- 79-92
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2394716637
- Cited by
- 75
- References
- 39
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.